Sponsor content
49 result(s) found, displaying 11 to 20
-
-
Australian Public Assessment Report (AusPAR)Lamzede (velmanase alfa) has been approved as an enzyme replacement therapy for the treatment of non-central nervous system manifestations in patients with alpha-mannosidosis.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ELFABRIO pegunigalsidase alfa 20 mg/10 mL concentrated injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LAMZEDE velmanase alfa 10 mg powder for injection vial.
-
Sep-2025Prescription medicine evaluationActive ingredient: metreleptin.
-
Cancellation by sponsorRequested by Chiesi Australia Pty Ltd
-
-
Prescription medicine registrationActive ingredients: pegunigalsidase alfa.
-
Prescription medicine registrationActive ingredients: velmanase alfa.
-
Designation or determinationOrphan drug